Frontlight ResearchEarly access
CompletedPhase 2
Epidiolex in Obsessive Compulsive Disorder and Related Disorders
Key facts
- Who runs it
- University of Chicago
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 4 people enrolled
- Started
- 14 Apr 2022
- Ended
- 1 Nov 2025
- Type of study
- Interventional
- Treatments tested
- Cannabidiol
- Record updated
- 29 July 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Men and women age 18-65
- Primary diagnosis of OCD, Hoarding Disorder, Skin Picking Disorder, Trichotillomania, or Tourette Syndrome
- YBOCS score of at least 18 at baseline
- Ability to understand and sign the consent form
Who cannot take part
- Use of any other psychotropic medication
- Previous treatment with Epidiolex
- Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination or labs
- Past 12-month DSM-5 psychiatric disorder other than OCD
- Cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent
- Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
- Subjects considered an immediate suicide risk based on the Columbia Suicide Severity Rating Scale (C-SSRS)
- Illegal substance use based on urine toxicology screening
- Initiation of psychological interventions within 3 months of screening
Where in United States
- University of ChicagoChicago, United States
About the trial
What the trial wants to find out
The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.
The group in the trial
- EpidiolexTreatment being tested
Epidiolex (2.5 mg/kg twice daily for one week) followed by Epidiolex (5mg/kg twice daily for two weeks)
Treatment: Cannabidiol
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study
- Record updated
- 29 July 2026